{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-010094","form_type":"8-K","ticker":"ORKA","cik":"0000907654","company_name":"Oruka Therapeutics, Inc.","filed_at":"2022-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.316472+00:00","generated_at":"2026-06-26T23:26:50.314105+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ARCA biopharma reports FY2021 net loss $19.3M, cash $53.4M; rNAPc2 data due late March 2022","bullets":["Net loss $19.3M ($1.39/share) vs $9.7M ($2.07/share) in FY2020; total operating expenses $19.3M.","Cash and equivalents $53.4M at Dec 31, 2021, up from $49.1M; runway through mid-2023.","R&D expenses $13.8M (up from $5.0M) driven by rNAPc2 trial; FY2022 R&D expected similar.","Topline data from Phase 2b ASPEN-COVID-19 trial for rNAPc2 anticipated last week of March 2022.","Gencaro paper published in Heart Rhythm O2; company evaluating PRECISION-AF trial feasibility."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-010094","json":"https://secwatch.observer/filing/0001564590-22-010094.json","markdown":"https://secwatch.observer/filing/0001564590-22-010094.md","text":"https://secwatch.observer/filing/0001564590-22-010094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000156459022010094/0001564590-22-010094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000156459022010094/abio-8k_20220314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T23:26:50.314105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}